These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
822 related articles for article (PubMed ID: 22564186)
1. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. Happold C; Roth P; Wick W; Schmidt N; Florea AM; Silginer M; Reifenberger G; Weller M J Neurochem; 2012 Jul; 122(2):444-55. PubMed ID: 22564186 [TBL] [Abstract][Full Text] [Related]
2. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells. Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841 [TBL] [Abstract][Full Text] [Related]
3. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Kitange GJ; Carlson BL; Schroeder MA; Grogan PT; Lamont JD; Decker PA; Wu W; James CD; Sarkaria JN Neuro Oncol; 2009 Jun; 11(3):281-91. PubMed ID: 18952979 [TBL] [Abstract][Full Text] [Related]
4. Transfection of a human glioblastoma cell line with liver-type glutaminase (LGA) down-regulates the expression of DNA-repair gene MGMT and sensitizes the cells to alkylating agents. Szeliga M; Zgrzywa A; Obara-Michlewska M; Albrecht J J Neurochem; 2012 Nov; 123(3):428-36. PubMed ID: 22888977 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study. Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131 [TBL] [Abstract][Full Text] [Related]
6. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762 [TBL] [Abstract][Full Text] [Related]
9. Temozolomide induced c-Myc-mediated apoptosis via Akt signalling in MGMT expressing glioblastoma cells. De Salvo M; Maresca G; D'agnano I; Marchese R; Stigliano A; Gagliassi R; Brunetti E; Raza GH; De Paula U; Bucci B Int J Radiat Biol; 2011 May; 87(5):518-33. PubMed ID: 21405945 [TBL] [Abstract][Full Text] [Related]
10. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952 [TBL] [Abstract][Full Text] [Related]
11. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
12. Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway. Huang H; Lin H; Zhang X; Li J Oncol Rep; 2012 Jun; 27(6):2050-6. PubMed ID: 22426504 [TBL] [Abstract][Full Text] [Related]
14. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W; Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102 [TBL] [Abstract][Full Text] [Related]
15. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. Hermisson M; Klumpp A; Wick W; Wischhusen J; Nagel G; Roos W; Kaina B; Weller M J Neurochem; 2006 Feb; 96(3):766-76. PubMed ID: 16405512 [TBL] [Abstract][Full Text] [Related]
16. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma. Tian T; Mingyi M; Qiu X; Qiu Y Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996 [TBL] [Abstract][Full Text] [Related]
17. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. Agnihotri S; Gajadhar AS; Ternamian C; Gorlia T; Diefes KL; Mischel PS; Kelly J; McGown G; Thorncroft M; Carlson BL; Sarkaria JN; Margison GP; Aldape K; Hawkins C; Hegi M; Guha A J Clin Invest; 2012 Jan; 122(1):253-66. PubMed ID: 22156195 [TBL] [Abstract][Full Text] [Related]
18. Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide. van Nifterik KA; van den Berg J; van der Meide WF; Ameziane N; Wedekind LE; Steenbergen RD; Leenstra S; Lafleur MV; Slotman BJ; Stalpers LJ; Sminia P Br J Cancer; 2010 Jun; 103(1):29-35. PubMed ID: 20517307 [TBL] [Abstract][Full Text] [Related]
19. N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death. Zhang J; Hummersone M; Matthews CS; Stevens MF; Bradshaw TD Oncology; 2015; 88(1):28-48. PubMed ID: 25277441 [TBL] [Abstract][Full Text] [Related]
20. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression. Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]